Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Histone deacetylase Stories

2009-04-17 07:30:00

Pharmacyclics to maintain all US Rights Conference Call to discuss the company's third quarter financial results is scheduled for April 23, 2009 at 11:00 a.m. EDT (8:00 a.m. PDT). SUNNYVALE, Calif., April 17 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has entered into a global strategic alliance with Servier, the leading French independent pharmaceutical company. The alliance will focus on the research, development, and commercialization of...

2009-04-03 12:51:19

Today, during the 87th General Session of the International Association for Dental Research, convening at the Miami Beach Convention Center, a group of scientists from Nihon University (Tokyo, Japan) will present findings suggesting that periodontal disease could act as a risk factor for reactivating latent HIV-1 in affected individuals.Latently infected cells harbor HIV-1 proviral DNA genomes integrated with heterochromatins, allowing for the persistence of transcriptionally silent...

2008-12-01 14:00:00

SINGAPORE, Dec. 1 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of a Phase 1/2 clinical trial of SB1518, a potent and orally-active JAK2 inhibitor, in leading medical centers in Australia for patients with chronic idiopathic myelofibrosis (CIMF). The trial is designed to evaluate the safety and tolerability of SB1518 in patients with CIMF and is expected to enrol up to 50 patients. The Phase 1 part of the study will assess the safety profile and evaluate the pharmacokinetic...

2008-10-21 09:00:12

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced today the presentation of a poster highlighting preclinical synergy of Cyclacel's sapacitabine when given in combination with histone deacetylating agents (HDAC) valproate and vorinostat. The data will be presented at the 20th Annual European Organization for Research and Treatment of Cancer-National Cancer Institute-American Academy of Cancer Research (EORTC-NCI-AACR) Symposium on "Molecular Targets and Cancer...

2008-10-03 12:00:05

MethylGene, a clinical stage biopharmaceutical company, has announced that Health Canada has approved the company's clinical trial application for MGCD290, a fungal Hos2 histone deacetylase inhibitor to be used in combination with azoles for the treatment of fungal infections. MethylGene expects to initiate a Phase I clinical trial in Canada in October 2008. The goal of this trial will be to assess the safety, pharmacokinetics and tolerability of the compound in healthy volunteers. MGCD290...

2008-09-16 12:00:10

WALTHAM, Mass., Sept. 16 /PRNewswire-FirstCall/ -- Repligen Corporation today reported publication of a preclinical study demonstrating that a novel histone deacetylase (HDAC) inhibitor improved disease symptoms in a transgenic animal model of Huntington's disease. The study, led by scientists at The Scripps Research Institute, demonstrated that oral administration of the drug candidate to the mice after the onset of symptoms slowed the progression of disease. Treated animals showed...

2008-08-21 09:15:00

U.S. chemists synthesize promising anti-cancer product WASHINGTON, Aug. 20 (Xinhua) -- Duke University announced on Wednesday that its chemists have patented an efficient technique for synthesizing a marine algae extract in sufficient quantities to now test its ability to inhibit the growth of cancerous cells. The researchers also deduced that this molecule, called largazole, acts on cells through the same chemical mechanism as other anti-cancer compounds on the market or in clinical trials....

2008-08-08 12:00:45

U.S. scientists say they've found a marine compound that inhibits cancer cell growth in lab tests and that might lead to new anti-cancer drugs. University of Florida College of Pharmacy researchers said the patented compound, called largazole, is derived from cyanobacteria that grow on coral reefs. "It's exciting because we've found a compound in nature that may one day surpass a currently marketed drug or could become the structural template for rationally designed drugs with improved...

e19540141b6b5bf03fa944a4adfcb636
2008-07-10 12:00:00

Researchers at The Children's Hospital of Philadelphia have manipulated cell activity that occurs during the interruption of blood flow to strongly protect heart tissue in animal studies. The finding has the potential to become an emergency treatment for heart attack patients, particularly since already existing drugs might be pressed into service to produce the protective effects. "Reduced blood flow, or ischemia, is a major problem in many organs, where it can lead to cell death and tissue...

2008-06-26 06:01:52

ValiRx plc (AIM:VAL, 'ValiRx'), the cancer therapeutics and diagnostics company, has announced promising in vivo results for its lead molecule VAL 101 which uses its gene silencing technology GeneICE(TM) in preclinical xenograph models of pancreatic cancer. Studies showed that the tumour growth was less than half the size of that seen in the control group. Based on these results, the Company will now initiate further preclinical studies with the aim of progressing VAL 101 toward...